This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hims & Hers Health, Inc. (HIMS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Health & Fitness Stocks to Buy for the Wellness Boom
by Nilanjan Choudhury
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.
Is First Trust Mid Cap Growth AlphaDEX ETF (FNY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FNY
The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx
by Zacks Equity Research
Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx are included in this Analyst Blog.
Should Vanguard S&P Small-Cap 600 ETF (VIOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOO
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
by Nalak Das
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Surging Earnings Estimates Signal Upside for Hims & Hers Health (HIMS) Stock
by Zacks Equity Research
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
HIMS Stock Dips Pre-Market Despite Q1 Earnings Beat, Gross Margin Down
by Zacks Equity Research
Hims & Hers' first-quarter 2025 performance reflects continued strength in its online revenue channel on the back of solid product demand and an increasing subscriber base.
Here's What Key Metrics Tell Us About Hims & Hers Health (HIMS) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Hims & Hers Health (HIMS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Trading Week Starts Out on the Soft Side
by Mark Vickery
Decent ISM Services numbers couldn't turn the tide on Monday's mild selloff.
Hims & Hers Health, Inc. (HIMS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 66.67% and 8.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Sell, or Hold FMS Stock Before Q1 Earnings?
by Zacks Equity Research
Fresenius Medical Care heads into the first quarter of 2025 with momentum from cost savings, innovation like the 5008X launch, and a steady recovery in U.S. treatment volumes.
Can Sustained Product Demand Drive HIMS Stock Before Q1 Earnings?
by Debanjana Dey
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the first quarter of 2025.
IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of -6.74% and 3.34%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
by Indrajit Bandyopadhyay
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
by Shaun Pruitt
Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
Hims & Hers vs. Teladoc: Which Telehealth Stock Is the Better Buy Now?
by Debanjana Dey
Both HIMS and TDOC are technology-intensive healthcare companies that leverage their strengths in the digital health space to enhance their platforms. Which one is a better investment? Let's see.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
TECH Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter.
Hims & Hers Health (HIMS) Stock Jumps 23.0%: Will It Continue to Soar?
by Zacks Equity Research
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
EMEA Growth & Product Launches to Support Boston Scientific Stock
by Zacks Equity Research
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Should You Buy, Sell, or Hold GE Healthcare Before Q1 Earnings?
by Zacks Equity Research
GEHC Q1 results are likely to reflect strong growth in Imaging, Ultrasound, and AI, fueled by robust procedure volumes and global partnerships despite China headwinds.